Compare TNC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | RCKT |
|---|---|---|
| Founded | 1870 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 534.2M |
| IPO Year | 1994 | N/A |
| Metric | TNC | RCKT |
|---|---|---|
| Price | $65.49 | $4.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $91.00 | $29.65 |
| AVG Volume (30 Days) | 350.2K | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,137,600,000.00 | N/A |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $5.28 | $97.68 |
| P/E Ratio | $27.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.18 | $2.19 |
| 52 Week High | $85.91 | $8.80 |
| Indicator | TNC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 47.40 |
| Support Level | $60.18 | $4.16 |
| Resistance Level | $84.24 | $4.51 |
| Average True Range (ATR) | 1.86 | 0.34 |
| MACD | 0.79 | -0.12 |
| Stochastic Oscillator | 85.44 | 11.85 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.